Context Therapeutics (CNTX) Share-based Compensation (2020 - 2026)
Context Therapeutics' (CNTX) quarterly Share-based Compensation came in at $409220.0 in Q1 2026, up 39.32% year-on-year from $293717.0 in Q1 2025, and up 140.77% quarter-over-quarter from -$1.0 million in Q4 2025.
Context Therapeutics (CNTX) Share-based Compensation (2020 - 2026) Analysis & Trends
Context Therapeutics has disclosed Share-based Compensation across 7 years of filings, most recently posting $409220.0 for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $409220.0, up 39.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $117678.0 (up 119.1% YoY), and the FY2025 annual result was $2175.0, changed N/A from the prior year.
- Share-based Compensation came in at $409220.0 for Q1 2026 at Context Therapeutics, up from -$1.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $565414.0 in Q3 2024 to a low of -$1.0 million in Q4 2025.
- The 5-year median for Share-based Compensation is $256051.0 (2023), against an average of $144982.4.
- Across the five-year window, Share-based Compensation jumped 742.54% in 2022 and sank 338.25% in 2024, its largest moves.
- Context Therapeutics' Share-based Compensation stood at $243637.0 in 2022, then grew by 5.1% to $256051.0 in 2023, then tumbled by 338.25% to -$610046.0 in 2024, then tumbled by 64.53% to -$1.0 million in 2025, then jumped by 140.77% to $409220.0 in 2026.
- The last three Share-based Compensation figures came in at $409220.0 (Q1 2026), -$1.0 million (Q4 2025), and $323081.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 26.47 Mn |
| 10 | Context Therapeutics | 166.57 Mn | 166.57 Mn | - | 409,220.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 409,220.00 |
| Mar 31, 2026 | 409,220.00 |
| Dec 31, 2025 | -1.00 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Sep 30, 2025 | 323,081.00 |
| Sep 30, 2025 | 323,081.00 |
| Jun 30, 2025 | 389,114.00 |
| Jun 30, 2025 | 389,114.00 |
| Mar 31, 2025 | 293,717.00 |
| Mar 31, 2025 | 293,717.00 |
| Dec 31, 2024 | -610,046.00 |
| Dec 31, 2024 | -610,046.00 |
| Sep 30, 2024 | 565,414.00 |
| Sep 30, 2024 | 565,414.00 |
| Jun 30, 2024 | -195,375.00 |
| Jun 30, 2024 | -195,375.00 |
| Mar 31, 2024 | 240,007.00 |
| Mar 31, 2024 | 240,007.00 |
| Dec 31, 2023 | 256,051.00 |
| Dec 31, 2023 | 256,051.00 |